Recruitment

• Planned/Actual:  [---]*
• (Anticipated or Actual) Date of First Enrollment:  2015/02/27
• Target Sample Size:  730
• Monocenter/Multicenter trial:  Multicenter trial
• National/International:  International

Inclusion Criteria

• Gender:  Both, male and female
• Minimum Age:  18   Years
• Maximum Age:  no maximum age

Additional Inclusion Criteria

- Participant must have documented multiple myeloma and measurable disease defined as:
1) monoclonal plasma cells in the bone marrow greater than or equal to (>=) 10
percent (%) or presence of a biopsy proven plasmacytoma; 2) measurable disease as
defined by any of the following: (a) immunoglobulin (Ig) G myeloma (serum monoclonal
paraprotein [M-protein] level >=1.0 gram/deciliter [g/dL] or urine M-protein level
>=200 milligram[mg]/24 hours[hrs]; or (b) IgA, IgM, IgD, or IgE multiple myeloma
(serum M-protein level >=0.5 g/dL or urine M-protein level >=200 mg/24 hrs); or (c)
light chain multiple myeloma (serum immunoglobulin free light chain >=10 mg/dL and
abnormal serum immunoglobulin kappa lambda free light chain ratio)

- Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
score of 0, 1, or 2

- Participants who are newly diagnosed and not considered for high-dose chemotherapy
due to: being age >=65 years; or participants less than (<) 65 years with presence of
important comorbid condition(s) likely to have a negative impact on tolerability of
high dose chemotherapy with stem cell transplantation. Sponsor review and approval of
participants below 65 years of age is required before randomization

- Women of childbearing potential must commit to either abstain continuously from
sexual intercourse or to use 2 methods of reliable birth control simultaneously as
deemed appropriate by the Investigator. Contraception must begin 4 weeks prior to
dosing

- Man, who is sexually active with a woman of child-bearing potential and has not had a
vasectomy, must agree to use an adequate contraception method as deemed appropriate
by the Investigator, and must also agree to not donate sperm during the study and for
4 weeks after last dose of lenalidomide and 4 months after last dose of daratumumab

Exclusion Criteria

- Participant has a diagnosis of primary amyloidosis, monoclonal gammopathy of
undetermined significance (presence of serum M-protein <3 g/dL; absence of lytic bone
lesions, anemia, hypercalcemia, and renal insufficiency related to the M-protein), or
smoldering multiple myeloma (asymptomatic multiple myeloma with absence of related
organ or tissue impairment end organ damage)

- Participant has a diagnosis of Waldenström's disease, or other conditions in which
IgM M protein is present in the absence of a clonal plasma cell infiltration with
lytic bone lesions

- Participant has a history of malignancy (other than multiple myeloma) within 5 years
before the date of randomization (exceptions are squamous and basal cell carcinomas
of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of
the Investigator, with concurrence with the Sponsor's medical monitor, is considered
cured with minimal risk of recurrence within 5 years)

- Participant has prior or current systemic therapy or SCT for multiple myeloma, with
the exception of an emergency use of a short course (equivalent of dexamethasone 40
mg/day for a maximum 4 days) of corticosteroids before treatment

- Participant has had radiation therapy within 14 days of randomization

- Participant has known chronic obstructive pulmonary disease (COPD) (defined as a
forced expiratory volume in 1 second [FEV1] <60% of predicted normal), persistent
asthma, or a history of asthma within the last 2 years (intermittent asthma is
allowed). Participants with known or suspected COPD or asthma must have a FEV1 test
during Screening

- Participant is known to be seropositive for history of human immunodeficiency virus
(HIV) or known to have active hepatitis B or hepatitis C